AARD vs ABSI

Aardvark Therapeutics, Inc. vs Absci Corporation — Valuation Comparison 2026

AARD

Biotechnology
Aardvark Therapeutics, Inc.
Quality
5.6
out of 10
Value Trap
Price
$4.20
Last close
Models
9/13
Active
VS

ABSI

Biotechnology
Absci Corporation
Quality
5.0
out of 10
Value Trap
29
LOW
Price
$6.08
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType AARD Fair ValueAARD Upside ABSI Fair ValueABSI Upside
Bayesian DCF Intrinsic $2.43 -55.5% $1.65 -72.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.44 -65.8% $0.13 -97.8%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for AARD vs ABSI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AARD vs ABSI — Which Stock Is More Undervalued?

AARD scores higher with a 5.6/10 quality rating vs ABSI's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aardvark Therapeutics, Inc. (AARD) and Absci Corporation (ABSI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AARD currently trades at $4.20 with a QOC of 5.6/10, while ABSI trades at $6.08 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).